Trial Profile
An Open-Label Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration of a Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine Fixed-Dose Combination Tablet in Healthy Japanese Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2015
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutical KK
- 05 Nov 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2015 New trial record